MRCP2-3679
A 50-year-old woman has been diagnosed with metastatic breast cancer that has spread to her liver and bones. She has undergone chemotherapy with the FEC combination and has responded well to the treatment. Due to her cancer being strongly ER positive, she has been prescribed anastrozole to maintain the disease response. However, during her follow-up appointment after two months, she appears to be unwell and is showing signs of jaundice. Her doctor has ordered blood tests, tumour markers, and a repeat CT scan of her chest, abdomen, and pelvis. Which of the following tumour markers are used to evaluate disease activity in metastatic breast cancer?